An interventional study of Endoscopic ultrasound examination in Pancreatic Disease, Pancreatic Cancer and Pancreatic Cyst, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Pancreatic Diseases with a site in United States — 13 open to participants now, 15 under way, 1 of them phase 3. Pancreatic Diseases · United States.
Among the 60 studies in Pancreatic Diseases with a site in United States, this one is the 12th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 54th registered.
184 studies on the registry are indexed under Pancreatic Diseases; 61 are open to participants now.
Browse Pancreatic Diseases studies →13 of the 60 studies in Pancreatic Diseases with a site in United States are open now. Recruiting first, the newest first:
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Orlando Health, Inc. · Sites in United States
Ages 18–100
Do Hyun Park · Sites in United States, Korea, Republic of
Ages 19+ · Healthy volunteers
Kaiser Permanente · Sites in United States
Ages 18+
Philip Polgreen · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Pancreatic Diseases studies recruiting now, 24 (59%) set no upper age limit and 4 (10%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 10 · Phase 4 3
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 96 across 104 interventional studies indexed under Pancreatic Diseases.
Median enrollment 76 across the 42 interventional studies, 287 across the 18 observational. Of the 36 that completed or were terminated, 21 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 60 have an industry lead sponsor. The 10 most frequent:
Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Orlando Health, Inc. has 2 studies filed under Pancreatic Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Pancreatic Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05474417Philip PolgreenThe Effects of the CF Carrier State on the Kidneys and Pancreas | 2026-12 |
| NCT06564571Orlando Health, Inc.Artificial Intelligence in Endoscopic Ultrasound | 2026-12 |
| NCT05603702Indiana UniversitySTTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis | 2027-03-31 |
| NCT07776353Kaiser PermanenteUnderstanding New Cachexia Subtypes Through Observational Epidemiological Research | 2027-05 |
| NCT07030348Do Hyun ParkEarly Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 60 studies in Pancreatic Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.
Endoscopic ultrasound (EUS) is the gold standard for evaluation and biopsy of lesions in the pancreaticobiliary tract, subepithelial lesions in the gastrointestinal tract and luminal cancer staging due to its high sensitivity and specificity. Endoscopic ultrasound examination is performed by echoendoscopes, which are endoscopes with an ultrasound probe at the distal end to allow endoscopic ultrasound evaluation. A new endoscopic ultrasound system - the EndoSound Visual System has now been developed for endoscopic ultrasound examination. The EndoSound Visual System is a device that can be attached externally to upper gastrointestinal endoscopes, thereby converting a standard endoscope into an echoendoscope which can then be used to perform an EUS examination.
The aim of this randomized trial is to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard echoendoscope will be used and EUS examination will be performed per standard of care.
Device: Endoscopic ultrasound examination
EndoSound Vision System will be used and EUS examination will be performed per standard of care.
Device: Endoscopic ultrasound examination
Endoscopic ultrasound examination will be performed.
Rate of successful completion of the requisite EUS examination
Rate of successful completion of the requisite examination during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, compared as a percentage of successfully completed examinations between the standard echoendoscope and Endosound Vision System.
Time frame: 1 day
Ease of maneuverability of the device
The ease of maneuverability during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, based on a rating scale of 1 to 5 (whereby 1 is the most easy to maneuver and 5 is the most difficult to maneuver).
Time frame: 1 day
Quality of EUS imaging
The quality of EUS imaging during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, based on a rating scale of 1 to 5 (whereby 1 is the best quality imaging and 5 is the worst quality imaging).
Time frame: 1 day
Ease of performing tissue acquisition
The ease of performing tissue acquisition during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, based on a rating scale of 1 to 5 (whereby 1 is the most easy to perform and 5 is the most difficult to perform).
Time frame: 1 day
Diagnostic adequacy of procured specimen on onsite evaluation
Rate of diagnostic adequacy of procured tissue specimen on onsite evaluation between the EndoSound Vision System and standard echoendoscopes.
Time frame: 7 days
Diagnostic adequacy of procured specimen in cell block
Rate of diagnostic adequacy of procured tissue specimen in cell block between the EndoSound Vision System and standard echoendoscopes.
Time frame: 7 days
Diagnostic accuracy of procured specimen
Rate of diagnostic accuracy of procured tissue specimen between the EndoSound Vision System and standard echoendoscopes.
Time frame: 7 days
Procedure duration
Duration of procedure between the EndoSound Vision System and standard echoendoscopes.
Time frame: 1 day
Rate of procedure-related adverse events
Rate of procedure-related adverse events between the EndoSound Vision System and standard echoendoscopes.
Time frame: 7 days
Procedure costs
Costs associated with the endoscopic ultrasound procedures between the EndoSound Vision System and standard echoendoscopes.
Time frame: 7 days
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
Of 32 interventional studies with no phase under Pancreatic Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 44. This study's planned 14 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Mar 2024 → Oct 2026, primary completion Dec 2026 → Dec 2027 and completion Dec 2027 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orlando Health, Inc.